59 related articles for article (PubMed ID: 38475661)
21. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma.
Bootsma M; McKay RR; Emamekhoo H; Bade RM; Schehr JL; Mannino MC; Singh A; Wolfe SK; Schultz ZD; Sperger J; Xie W; Signoretti S; Kyriakopoulos CE; Kosoff D; Abel EJ; Helzer KT; Rydzewski N; Bakhtiar H; Shi Y; Blitzer G; Bassetti M; Floberg J; Yu M; Sethakorn N; Sharifi M; Harari PM; Choueiri TK; Lang JM; Zhao SG
J Clin Oncol; 2022 Nov; 40(31):3633-3641. PubMed ID: 35617646
[TBL] [Abstract][Full Text] [Related]
22. Robotic-assisted tumor enucleation versus standard margin partial nephrectomy: Perioperative, renal functional, and oncologic outcomes for low and intermediate complexity renal masses.
Patel HD; Koehne EL; Gali K; Lanzotti NJ; Rac G; Desai S; Pahouja G; Quek ML; Gupta GN
Urol Oncol; 2022 Jul; 40(7):347.e9-347.e16. PubMed ID: 35551863
[TBL] [Abstract][Full Text] [Related]
23. Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature.
Geertsen L; Koldby KM; Thomassen M; Kruse T; Lund L
Eur Urol Open Sci; 2022 Mar; 37():27-35. PubMed ID: 35106503
[TBL] [Abstract][Full Text] [Related]
24. Oncological Outcomes of Patients With Different Pathological Features of pT3a Renal Tumor: A Systematic Review and Quantitative Synthesis.
Guo P; Wang Y; Han Y; Wei D; Zhao J; Li M; Jiang Y; Luo Y
Front Oncol; 2021; 11():678459. PubMed ID: 34150642
[TBL] [Abstract][Full Text] [Related]
25. Preoperative Assessment of Renal Sinus Invasion by Renal Cell Carcinoma according to Tumor Complexity and Imaging Features in Patients Undergoing Radical Nephrectomy.
Kim JH; Park KJ; Kim MH; Kim JK
Korean J Radiol; 2021 Aug; 22(8):1323-1331. PubMed ID: 34047502
[TBL] [Abstract][Full Text] [Related]
26. Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma.
Kim YJ; Kang Y; Kim JS; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park D; Park WY; Kang M
Sci Rep; 2021 Mar; 11(1):5600. PubMed ID: 33692449
[TBL] [Abstract][Full Text] [Related]
27. Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma.
Nocera L; Stolzenbach LF; Ruvolo CC; Wenzel M; Tian Z; Rosiello G; Bravi CA; Candela L; Basile G; Larcher A; Shariat SF; Bertini R; Capitanio U; Salonia A; Montorsi F; Briganti A; Karakiewicz PI
Eur J Surg Oncol; 2021 May; 47(5):1187-1190. PubMed ID: 33168336
[TBL] [Abstract][Full Text] [Related]
28. Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive Factors.
Veccia A; Falagario U; Martini A; Marchioni M; Antonelli A; Simeone C; Cormio L; Capitanio U; Mir MC; Derweesh I; Van Poppel H; Porpiglia F; Autorino R
Eur Urol Focus; 2021 May; 7(3):574-581. PubMed ID: 32571744
[TBL] [Abstract][Full Text] [Related]
29. Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma.
Lasseter K; Nassar AH; Hamieh L; Berchuck JE; Nuzzo PV; Korthauer K; Shinagare AB; Ogorek B; McKay R; Thorner AR; Lee GM; Braun DA; Bhatt RS; Freedman M; Choueiri TK; Kwiatkowski DJ
Genet Med; 2020 Aug; 22(8):1366-1373. PubMed ID: 32341571
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of the sub-classification of stage pT3a renal tumors by perinephric and sinus fat invasion.
Zhu D; Cao J; Zhi C; Guo T; Li Y; Lang Z; Li G
Oncol Lett; 2020 Mar; 19(3):1721-1726. PubMed ID: 32194664
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors.
Smith CG; Moser T; Mouliere F; Field-Rayner J; Eldridge M; Riediger AL; Chandrananda D; Heider K; Wan JCM; Warren AY; Morris J; Hudecova I; Cooper WN; Mitchell TJ; Gale D; Ruiz-Valdepenas A; Klatte T; Ursprung S; Sala E; Riddick ACP; Aho TF; Armitage JN; Perakis S; Pichler M; Seles M; Wcislo G; Welsh SJ; Matakidou A; Eisen T; Massie CE; Rosenfeld N; Heitzer E; Stewart GD
Genome Med; 2020 Feb; 12(1):23. PubMed ID: 32111235
[TBL] [Abstract][Full Text] [Related]
32. Upstaging to pT3a disease in patients undergoing robotic partial nephrectomy for cT1 kidney cancer: Outcomes and predictors from a multi-institutional dataset.
Veccia A; Antonelli A; Minervini A; Mottrie A; Dell'Oglio P; Ashrafi AN; Larcher A; Eun D; Bradshaw A; Amparore D; Brassetti A; Hampton LJ; Simeone C; Mari A; Carini M; De Naeyer G; Yang K; Capitanio U; Simone G; Porpiglia F; Derweesh I; Aron M; Autorino R
Urol Oncol; 2020 Apr; 38(4):286-292. PubMed ID: 31956077
[TBL] [Abstract][Full Text] [Related]
33. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria.
Hamilton ZA; Capitanio U; Pruthi D; Ghali F; Larcher A; Patel DN; Eldefrawy A; Patel S; Cotta BH; Bradshaw AW; Meagher MF; Miller NS; Carenzi C; Wan F; Liss MA; McGregor T; Montorsi F; Derweesh IH
Urology; 2020 Apr; 138():60-68. PubMed ID: 31836465
[TBL] [Abstract][Full Text] [Related]
34. Impact of pathological T3a upstaging on oncological outcomes of clinical T1 renal cell carcinoma: a meta-analysis.
Chen L; Deng W; Liu X; Wang G; Fu B
J Cancer; 2019; 10(20):4998-5006. PubMed ID: 31598172
[No Abstract] [Full Text] [Related]
35. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
36. Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden.
Maia MC; Bergerot PG; Dizman N; Hsu J; Jones J; Lanman RB; Banks KC; Pal SK
Kidney Cancer; 2017 Jul; 1(1):65-70. PubMed ID: 30334006
[No Abstract] [Full Text] [Related]
37. Outcomes of pathologic stage T3a renal cell carcinoma up-staged from small renal tumor: emphasis on partial nephrectomy.
Lee H; Lee M; Lee SE; Byun SS; Kim HH; Kwak C; Hong SK
BMC Cancer; 2018 Apr; 18(1):427. PubMed ID: 29661179
[TBL] [Abstract][Full Text] [Related]
38. Tumor size and Fuhrman grade further enhance the prognostic impact of perinephric fat invasion and renal vein extension in T3a staging of renal cell carcinoma.
Chen K; Lee BL; Huang HH; Tan BY; Lee LS; Ng LG; Lau W; Yuen JS
Int J Urol; 2017 Jan; 24(1):51-58. PubMed ID: 27757999
[TBL] [Abstract][Full Text] [Related]
39. Oncological outcomes of patients with incidental pathological T3a stage small renal cell carcinoma after partial nephrectomy.
Lee C; You D; Yoo S; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1651-7. PubMed ID: 27193144
[TBL] [Abstract][Full Text] [Related]
40. Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes.
Nayak JG; Patel P; Saarela O; Liu Z; Kapoor A; Finelli A; Tanguay S; Rendon R; Moore R; Black PC; Lacombe L; Breau RH; Kawakami J; Drachenberg DE
Urology; 2016 Aug; 94():154-60. PubMed ID: 27041471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
